Provide feedbackProvide feedback

Home :: Gastroenterology

"Vigilant" monitoring needed for adverse events with cyclosporine for IBD

Monday, May 12 2008 | Comments

NEW YORK (Reuters Health) - Cyclosporine therapy for inflammatory bowel disease (IBD) is associated with a high frequency of minor and major adverse events, according to a retrospective study.

"Although not all these events can be clearly attributed to cyclosporine use alone, we suggest vigilant monitoring at tertiary care centers with experience in the treatment of severe IBD as well as experience with the use of cyclosporine," write the researchers in the April issue of the...

NEW YORK (Reuters Health) - Cyclosporine therapy for inflammatory bowel disease (IBD) is associated with a high frequency of minor and major adverse events, according to a retrospective study.

"Although not all these events can be clearly attributed to cyclosporine use alone, we suggest vigilant monitoring at tertiary care centers with experience in the treatment of severe IBD as well as experience with the use of cyclosporine," write the researchers in the April issue of the American Journal of Gastroenterology.

Moderate- to high-dose cyclosporine is known to be effective in the acute treatment of IBD; however, data on the adverse effects of cyclosporine in this patient population are lacking, Dr. Daniel H. Present from Mount Sinai Medical Center, New York, and colleagues note in the report.

They reviewed the records of 111 consecutive patients with IBD (64 ulcerative colitis, 47 Crohn's disease) who were treated with intravenous cyclosporine (4 mg/kg/day) followed by oral cyclosporine (8 mg/kg/day), with dose adjustment as needed based on serum creatinine. The average treatment duration was 9.3 months.

Major adverse events occurred in 17 patients (15.3%), including two deaths (1.8%), one of which was clearly related to complications of cyclosporine therapy, the team reports.

Nephrotoxicity occurred in 27 patients (24%), but in 21 patients serum creatinine returned to normal with dose adjustment. Nephrotoxicity severe enough to warrant discontinuation of therapy occurred in 6 patients (5.4%). "We strictly defined nephrotoxicity as a serum creatinine of greater than 1.4 mg/dL (123 micromoles per liter) or a rise by at least 33% over baseline creatinine," the authors note.

Seven patients (6.3%) developed severe infections, four had seizures (3.6%) and one developed anaphylaxis (0.9%).

Minor adverse events associated with cyclosporine therapy were frequent but did not require dose adjustment in most cases. Minor adverse events comprised: paresthesias (51%), hypomagnesemia (42%), hypertension (39%), hypertrichosis (27%), headache (23%), minor nephrotoxicity (19%), abnormal liver function tests (19%), minor infections (15%), hyperkalemia (13%) and gingival swelling (4%).

The researchers add: "The role of cyclosporin versus biological treatments in severe ulcerative colitis remains to be defined since both agents have a significant toxicity profile."

Am J Gastroenterol 2008;103:937-943.

Latest News

Cystatin C tracks renal function decline in diabetes Verusmed

Monday, May 12 2008 | Comments
NEW YORK (Reuters Health) - Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in patients with type 1 diabetes, Australian researchers report in the May issue of Diabetes Care.

Moreover, lead investigator Dr. Erosha Premaratne told Reuters Health, "There are many potential clinical benefits of using cystatin C for longitudinal monitoring of renal function." These include greater simplicity and reduced...

Colonic enemas effective for dysfunctional voiding in children with constipation Verusmed

Monday, May 12 2008 | Comments
NEW YORK (Reuters Health) - Dysfunctional voiding combined with chronic constipation can be cured by a course of colonic washout enemas, according to results of a Dutch study published in the April issue of Urology.

"Dysfunctional voiding sometimes coincides with long-lasting defecation disturbances," write Dr. Rafal Chrzan and colleagues from University Children's Hospital UMC Utrecht. "This condition is called dysfunctional elimination syndrome," they note. "The term indicates...


Amitriptyline may alleviate irritable bowel symptoms in teens Verusmed

Friday, May 09 2008 | Comments
NEW YORK (Reuters Health) - Treatment with the tricyclic antidepressant amitriptyline can reduce symptoms and improve quality of life in adolescents with irritable bowel syndrome (IBS), the results of a small study suggest.

"While research has shown that amitriptyline is effective for adults with IBS, only peppermint oil has been studied in children with this disorder in a double-blind, placebo-controlled fashion," lead author Dr. Ron J. Bahar, from the University of California at...

New low-volume bowel cleansing solution effective, more acceptable Verusmed

Friday, May 09 2008 | Comments
NEW YORK (Reuters Health) - For bowel cleansing before colonoscopy, a new 2 liter solution of polyethylene glycol (PEG) plus ascorbic acid is as effective as the standard 4 liter PEG plus electrolytes solution, and is more acceptable to patients, researchers report in the American Journal of Gastroenterology for April.

The addition of ascorbic acid appears not only to improve the taste of the gut lavage solution, it also reduces the effective volume of solution needed for adequate...